Analysis of the Transcriptome of Group A Streptococcus in Mouse Soft Tissue Infection by Graham, Morag R. et al.
Immunopathology and Infectious Diseases
Analysis of the Transcriptome of Group A
Streptococcus in Mouse Soft Tissue Infection
Morag R. Graham,* Kimmo Virtaneva,*
Stephen F. Porcella,* Donald J. Gardner,†
R. Daniel Long,† Diane M. Welty,†
William T. Barry,‡ Claire A. Johnson,*
Larye D. Parkins,* Fred A. Wright,‡ and
James M. Musser*§
From the Laboratory of Human Bacterial Pathogenesis,* Rocky
Mountain Veterinary Branch,† Rocky Mountain Laboratories,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Hamilton, Montana; the Department of
Biostatistics,‡ University of North Carolina at Chapel Hill, Chapel
Hill, North Carolina; and the Center for Molecular and
Translational Human Infectious Diseases Research,§ The
Methodist Hospital Research Institute and Department of
Pathology, The Methodist Hospital, Houston, Texas
Molecular mechanisms mediating group A Streptococ-
cus (GAS)-host interactions remain poorly understood
but are crucial for diagnostic, therapeutic, and vaccine
development. An optimized high-density microarray
was used to analyze the transcriptome of GAS during
experimental mouse soft tissue infection. The transcrip-
tome of a wild-type serotype M1 GAS strain and an
isogenic transcriptional regulator knockout mutant
(covR) also were compared. Array datasets were verified
by quantitative real-time reverse transcriptase-polymer-
ase chain reaction and in situ immunohistochemistry.
The results unambiguously demonstrate that coordi-
nated expression of proven and putative GAS virulence
factors is directed toward overwhelming innate host
defenses leading to severe cellular damage. We also
identified adaptive metabolic responses triggered by nu-
trient signals and hypoxic/acidic conditions in the host,
likely facilitating pathogen persistence and prolifera-
tion in soft tissues. Key discoveries included that oxida-
tive stress genes, virulence genes, genes related to
amino acid and maltodextrin utilization, and several
two-component transcriptional regulators were highly
expressed in vivo. This study is the first global analysis
of the GAS transcriptome during invasive infection.
Coupled with parallel analysis of the covR mutant
strain, novel insights have been made into the regula-
tion of GAS virulence in vivo, resulting in new avenues
for targeted therapeutic and vaccine research. (Am J
Pathol 2006, 169:927–942; DOI: 10.2353/ajpath.2006.060112)
Skin and soft tissue infections are most commonly caused
by bacteria and account for 7 to 10% of hospitalizations in
North America.1 Substantial portions are caused by Strep-
tococcus pyogenes (group A streptococci; GAS). A major
human pathogen, GAS is associated with millions of skin
and throat infections each year.2 Serious complications af-
ter infection, namely rheumatic fever, glomerulonephritis,
and reactive arthritis, can follow even relatively mild GAS
infections and cause significant morbidity worldwide.3,4
Some GAS infections rapidly progress to life-threatening
invasive diseases such as septicemia, streptococcal toxic
shock syndrome, and necrotizing fasciitis, requiring life-
saving interventions in the form of aggressive fluid replace-
ment, general supportive measures, and/or emergent sur-
gical debridement.2–4 Nearly 15,000 cases of invasive GAS
disease and an estimated 1300 deaths occur annually in
the United States.5 Epidemiological data also suggest in-
creased incidence and severity of GAS infections in recent
years.2,6,7 Because progression to systemic toxicity and
shock can occur throughout a span of hours, early recog-
nition and initiation of aggressive therapies are essential.
Molecular mechanisms mediating GAS-host interactions
remain poorly understood but are crucial for rapid diagnos-
tic, therapeutic, and vaccine development.3,4 As a conse-
quence, concerted efforts have been made to identify reg-
ulatory mechanisms involved in coordinating the in vitro
expression of GAS virulence determinants. Genes have
been identified that regulate production of proven and pu-
tative virulence factors, and several of these regulators are
known to respond to environmental changes in vitro or to
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specific phases of the bacterial growth cycle.3,8 However,
far less is known about gene expression in vivo during GAS
infection of mammalian hosts.9–11 Infection sites or the host
circulation environment are complex, and their influence on
bacterial gene regulation cannot be simulated in vitro.12
Hence, further understanding of GAS host/pathogen molec-
ular interactions requires analysis of in vivo conditions that
better approximate the natural history of infections.
Streptococcal soft tissue infections, such as cellulitis
involving the subdermal layers and superficial fascia,
often commence with nonspecific symptoms such as
erythema, heat, soft tissue edema, generalized pain,
and sometimes serosanguinous bullae.6,7 Progression
to diffuse necrosis of subcutaneous and deep fascia
(necrotizing fasciitis) often occurs without overt skin
injury13 and leads to development of vasculitis, intra-
vascular thrombosis, and tissue gangrene. Histopa-
thology of debrided soft tissue reveals acute inflamma-
tion of subcutaneous tissue with bacterial aggregates
and multifocal necrosis. Mice subcutaneously injected
with GAS also develop inflamed bullae that later ulcer-
ate; diffuse inflammatory infiltrates with high bacterial
counts, and diffuse tissue necrosis including throm-
bosed vessels.3 In a previous study,14 we measured a
subset (n  17) of GAS transcripts expressed in vivo 2
days after inoculation with a wild-type (WT) serotype
M1 GAS strain and a covR isogenic deletion mutant of
a key GAS two-component regulatory system (TCS)
referred to as CovR-CovS (Cov, control of virulence). In
this present study we have expanded our investigation
by using a custom high-density array for whole GAS
transcriptome analysis in the murine soft tissue infec-
tion model. The data presented here provide substan-
tial new information about GAS survival strategies in
soft tissue. The most abundant GAS transcripts de-
tected were found to encode extracellular proteins that
are key virulence determinants. Other expressed GAS
genes are potential targets for therapeutic intervention
and warrant further study.
Materials and Methods
Bacterial Strains
Serotype M1 GAS strains commonly cause pharyngitis
and invasive infections.2 Strain MGAS5005 (no. BAA-
947; American Type Culture Collection, Rockville, MD),
a WT clinical strain (serotype M1), and its isogenic
covR derivative strain (JRS950) have been de-
scribed.14 –16 Bacteria were cultured statically on Tryp-
ticase soy agar containing 5% sheep blood agar (Bec-
ton-Dickinson, Cockeysville, MD) or in Todd-Hewitt
broth (Becton-Dickinson) containing 0.2% (w/v) yeast
extract (THY; Difco Laboratories, Detroit, MI), at 37°C
in an atmosphere containing 5% CO2. For generating
inoculum, cells were harvested from THY at late-expo-
nential phase (OD600 0.75) to limit infectivity differ-
ences across strains associated with up-regulated
capsule biosynthesis in strain JRS950, which is maxi-
mal in the early-to-mid exponential growth phases.
Mouse Soft Tissue Infection Model
This model of GAS soft tissue infection has been used
extensively to study bacterial-host interactions.14,17,18
Our experimental protocol was approved by the Institu-
tional Animal Care and Use Committee, National Institute
of Allergy and Infectious Diseases. Outbred, immuno-
competent, hairless male Crl:SKH1-hrBR mice (5 weeks
old; 20 to 25 g) (Charles River Breeding Laboratories, Bar
Harbor, ME), maintained on standard mouse food and
water ad libitum, were randomly assigned to one of two
treatment groups (WT or covR mutant GAS strain, n 
27 each; four mice per cage). Immediately before inoc-
ulation, the animals were weighed and anesthetized with
isoflurane (Aerrane; Ohmeda Caribe, Guayama, Puerto
Rico) inhalation. The animals were inoculated subcuta-
neously in the dorsal side with 0.1 ml of pyrogen-free
phosphate-buffered saline (PBS) (diluent) or 3  107
colony-forming units of MGAS5005 (WT) or JRS950
(covR). The actual colony-forming units of viable bacte-
ria inoculated were verified by growth on blood agar.
To blind the investigator, cage numbers were reas-
signed after inoculation, and the blind was broken after
data analysis. Methods for clinical measurements and
analysis of gross pathologies have been reported previ-
ously for this soft tissue model of infection,14,19 and data
are found in Supplementary Tables 1 and 2 (see http://
ajp.amjpathol.org). Length (L) and width (W) values were
used to calculate abscess volume [V  4/3(L/2)2 
(W/2)] and area [A  (L/2)  (W/2)], using equations for
a spherical ellipsoid as described.14
At 53 hours after inoculation, mice were euthanized and
weighed, the infection site was swabbed to confirm GAS
infection, and tissue was obtained from each animal via a
biopsy that included dermis and underlying soft tissue le-
sions. Tissues were wrapped in aluminum foil, snap-frozen
in liquid nitrogen, and stored at 80°C until RNA was iso-
lated. Three additional control mice injected with sterile
saline failed to show symptoms of clinical infection and did
not grow GAS bacterial colonies on plating.
Experimental Design
A one-factor experimental design with two treatment
(strain) levels was used. Samples were randomized at the
start of procedures, and care was taken to ensure that
batches of sample preparation, array hybridizations, and
posthybridization washes were not confounded with
treatment. Additional experimental design details are out-
lined in the Supplementary Materials and Methods (see
http://ajp.amjpathol.org).
RNA Isolation
Frozen tissue extracts were divided into three aliquots
from which RNA was purified. Tissue extracts were pul-
verized with a series of sharp blows delivered with a
3-pound drill hammer (Razor-Back; Union Tools Inc., Co-
lumbus, OH). Cell lysis and RNA isolation were con-
ducted with a FastRNA kit (MP Biomedicals, Irvine, CA)
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as described.20 The concentrate was fragmented with a
Qiashredder (Qiagen, Inc., Valencia, CA) and the iso-
lated total RNA (containing both bacterial and host RNA)
was purified in 96-well format using a plate centrifugation
system (RNeasy 96; Qiagen), with on-column DNase I
treatment and posttreatment with DNAFree (Ambion, Inc.,
Austin, TX) as described.10,20 RNA integrity was as-
sessed with a 2100 bioanalyzer (Agilent Technologies,
Palo Alto, CA)10,20 and by measurement of the A260/A280
ratios. Absence of contaminating bacterial genomic DNA
was confirmed by real-time polymerase chain reaction
(PCR). Two RNA aliquots were pooled to perform the
microarrays; the remaining extract was used for real-time
RT-PCR validation.
Bacterial Target Preparation
Fifty-four microarray targets were prepared primarily as
described.10,20 Briefly, each RNA sample was divided
into two to three aliquots of 10-g total RNA (each) to
which 0.8 g of bacteriophage MS2 carrier RNA (Roche
Applied Biosciences, Indianapolis, IN) was added. Con-
trol spike transcripts (130 pmol/L) were added to each
RNA aliquot, and 5 g of random primers (Invitrogen,
Carlsbad, CA) were annealed (10 minutes at 70°C, 10
minutes at 25°C). cDNA synthesis reactions and postsyn-
thesis RNA digestion were performed as described.10,20
In brief, the resultant cDNA was purified using Qiaquick
96 kit (Qiagen) according to the manufacturer’s recom-
mendation. For cDNA fragmentation, 3 g of cDNA and
0.75 U of DNase I (Roche Biosciences) were used (10
minutes at 37°C, 10 minutes at 98°C). The desired cDNA
size range of 50 to 200 bases was verified by separating
200 ng of cDNA on a RNA 6000 Nano LabChip (Agilent)
using the 2100 BioAnalyzer (Agilent) with no added dye
in the loading buffer. The fragmented cDNA was then
end-labeled with biotin-ddUTP as per the Enzo BioArray
terminal labeling kit (60 minutes at 37°C; Enzo Diagnos-
tics, New York, NY) and pooled with other end-labeled
cDNAs of the same sample. Samples were hybridized to
54 Rocky Mountain Laboratory (RML) Affymetrix custom
GAS arrays, as described.10,20
Affymetrix GeneChip Custom Array
The Affymetrix Inc. (Santa Clara, CA) custom high-den-
sity anti-sense oligonucleotide GeneChip array (desig-
nated RMLChip herein) has been described.10,16 It con-
tains redundant probe sets representing more than 90%
coverage of predicted coding regions (1869 ORFs) en-
coded by the MGAS5005 genome.16 Each probe set is
used to detect the presence of a single transcript, and
several GAS transcripts (genes) are represented by more
than one probe set. For in-depth RMLChip details, refer to
the Supplementary Materials and Methods (see
http://ajp.amjpathol.org).
GeneChip Hybridization
Target hybridizations, washing, staining, and scanning
were performed by the National Institute of Allergy and
Infectious Diseases Affymetrix core facility (Science Ap-
plications International Corp., Frederick, MD) using a
GeneChip hybridization oven and the Pseudomonas
aeruginosa hybridization protocol (Affymetrix), as de-
scribed.20 The hybridization solution volume used was
200 l because the RMLChip is a standard size array.
Each array was scanned at 570 nm at 3-m resolution
with a GeneArray scanner. Scanned DAT-image files
were analyzed with Affymetrix Microarray Suite (MAS) 5.0
software. The raw CEL files have been submitted to Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo).
Downstream genome analysis was accomplished using
MicrobesOnline (available at http://www.microbesonline.
org)21 and in-house bioinformatics analysis.
Statistical Analysis
Model-based expression estimates for each gene were
obtained using the PM-MM difference model22 of dCHIP
software as described.20 The gene expression estimates
were normalized across samples by quadratic scaling to
an artificial array with the median expression for each
gene.23 Two-dimensional scatterplots of expression esti-
mates were generated for all pairs of samples within the
same treatment group to examine uniformity across sam-
ples. Hierarchical clustering and principal components
analyses also were performed (Supplementary Figure 1,
see http://ajp.amjpath.org). Five arrays with poorer quality
RNA and low within-strain correlation were removed as
outliers. Downstream data analysis was performed with
MGAS5005 genome-specific probe sets using Partek Pro
(Partek Inc., St. Louis, MO). To evaluate expression rank-
ings, absolute square root-transformed expression esti-
mates were integer-ranked, starting from 1 for the most
abundant GAS transcript and increasing correspondingly
with decreasing transcript detection. To investigate ex-
pression correlations, standard Pearson correlation coef-
ficients were determined for select genes versus all other
genes using Partek Pro. To investigate strain effects,
expression estimates were analyzed by analysis of vari-
ance with treatment (WT versus covR strain) as a fixed
effect. Technical variables included in the analysis in-
cluded batches for sample preparation, sample hybrid-
ization, and posthybridization washes (Supplementary
Figure 2, see http://ajp.amjpath.org). Final results were
subjected to multiple testing correction using Q  0.05
false discovery rate cutoff values.24,25 Using rigorous
permutation-based statistics, we also performed signifi-
cance analysis of function and expression (termed
SAFE)26 to assess the significance of multiple gene cat-
egories in GAS in vivo transcriptional responses across
strains. A detailed description of the procedures used is
provided in the Supplementary Materials and Methods
(see http://ajp.amjpathol.org).
Quantitative Real-Time Reverse Transcriptase
(RT)-PCR Analysis
Real-time reverse transcriptase (RT)-PCR assays were
conducted to validate a subset of the microarray data.
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Eight oligonucleotide primer pairs and 6FAM-labeled
probe sets (specific for cfa, dppA, emm1, sceD, sclA, sic,
slo, and speA2) were used to perform target amplification
and detection from cDNA templates in 20-l multiplex
two-step RT-PCR reactions as described.20 Targets were
selected to encompass the full range of expression signal
values identified by array transcriptome analysis. Target
abundance was normalized to JOE-labeled internal ref-
erence transcript proS, which is transcribed at constant
levels throughout the GAS growth cycle in vitro and not
affected by covR inactivation.14 Differences in median
values were evaluated for statistical significance with the
Mann-Whitney rank sum test at the P  0.001 level.
Sampling and Histological Assessment
Tissue used for histological examination was prepared from
mice subcutaneously inoculated with 2.4  107 colony-
forming units of GAS strains MGAS5005 or covR JRS950
(n  16, each strain) as described above, except that
4-week-old (15 to 20 g) female Crl:SKH1-hrBR mice
(Charles River Breeding Laboratories) were used. Six ani-
mals inoculated with PBS were used as controls. For as-
sessment of bacterial content, histopathology, and bacterial
protein expression, mice were euthanized 48 hours after
inoculation, and the skin and underlying soft tissue were
removed from inoculation sites and fixed in 10% buffered
formalin before embedding in paraffin. To assess the pres-
ence of bacteria and pathological changes, formalin-fixed
tissues were sectioned and stained with gram stain or he-
matoxylin and eosin (H&E) stain (Sigma, St. Louis, MO),
according to standard methodologies. An Olympus model
BX51 microscope equipped with a Q-FIRE (Olympus, To-
kyo, Japan) camera was used for image capture.
Immunohistochemical Analysis
Rabbit polyclonal anti-GAS antibodies made against pu-
rified recombinant GAS proteins27 were used for immu-
nostaining. Paraffin-embedded tissues were cut into
4-m sections and stained with antibodies specific for 16
bacterial antigens [M5005_Spy ORF numbers desig-
nated in square brackets] (AtmB [0271]; PrtS [0342];
MtsA [0368]; IdeS/Mac [0668]; [0942]; PstS [0955];
SpeA2 [0996]; MalE [1058]; PrsA [1133]; [1308]; HtsA/
SiaA [1528]; Shp [1529]; DppA [1704]; Lmb [1711]; Fba
[1713]; SIC [1718]) using biotinylated secondary anti-
bodies in combination with horseradish peroxidase-cou-
pled streptavidin (DAKO Corp., Carpinteria, CA) and the
substrate AEC (BioGenex, San Ramon, CA). To evaluate
nonspecific staining, a polyclonal antibody recognizing a
control peptide (Bethyl Laboratories, Montgomery, TX)
was used as negative control. The M3.1/1-24 control
peptide, representing the N-terminal peptide of serotype
M3 Emm3.1, was used because this peptide is not en-
coded within the genome of the serotype M1 WT strain
MGAS5005.16 All immunohistochemically (IHC) stained
sections were counterstained with Mayer’s hematoxylin
and mounted using synthetic aqueous-based mounting
medium (DAKO Faramount).
Results
Gross and Microscopic Pathology
PBS-inoculated skin sections from the immunocompetent
Crl:SKH1-hrBR mice were histologically normal whereas
animals inoculated with either WT or covR strain dem-
onstrated subcutaneous foci of suppurative inflammation
with adjacent infiltrating polymorphonuclear lymphocytes
(PMNs), dermatitis, loss of stratum cornea, fibrin thrombi
in the small vessels, and varying degrees of dermal and
epidermal necrosis with degenerate and necrotic neutro-
phils (Figure 1). covR-inoculated mice had more exten-
sive inflammation (panniculitis), ulcerated epidermis and
necrosis of subcutaneous tissue fascia with some areas
of muscle involvement (myonecrosis), and faster ulcer
development (Figure 1), thus confirming previous reports
of the hypervirulence of covR mutant GAS strains. All
gram stains of infected tissues revealed aggregates of
gram-positive cocci in multiple focal planes (Figure 2).
Taken together, these observations provide histopatho-
logical evidence of high bacterial loads and diffuse tissue
necrosis analogous to progressive human infections.
Abundant in Vivo GAS Transcripts
The vast majority of the top 200 detected GAS transcripts
in WT-inoculated tissue extracts from soft tissue infection
encode products involved in protein synthesis (n  22),
information processing (n  15), carbohydrate metabo-
lism (n  15), membrane transport (n  15), stress ad-
aptation (n  15), or cellular processing (n  14) are
shown in Supplementary Table 3 (see http://ajp.
amjpathol.org) and discussed in more detail below. In
addition, transcripts with virulence (n  10), cell wall
metabolism (n  8), and unknown functional annotation
(n  9) also were detected at high levels (Supplementary
Table 3, see http://ajp.amjpathol.org) implying that repli-
cation, protein synthesis, cellular remodeling, and stress
adaptation are important functions during soft tissue in-
fection. Proteins encoded by five GAS transcripts found
to be abundant in the infected tissue [penicillin-binding
protein (PBP) 1A (pbp1a), a protein translation initiation
factor (tdcF), a putative lipoprotein (atmB), a hypothetical
protein of unknown function (M5005_Spy1104), and DNA
polymerase III (polC) involved in DNA replication] have
been previously detected by in vivo-induced antigen
technology (IVIAT) using convalescent human and
mouse28 sera.
The virulence-associated sic and emm transcripts, en-
coding the anti-phagocytic extracellular streptococcal in-
hibitor of complement (SIC) and hypervariable surface
antigen designated M protein, ranked within the top
seven most abundant transcripts in WT-inoculated ani-
mals and within the top 11 in mutant-inoculated mice
(Supplementary Table 3, see http://ajp.amjpathol.org). Six
cotranscribed ORFs (M5005_Spy0971-6), encoding hy-
pothetical and general stress proteins related to Gls24 of
Enterococcus faecalis, were among the 20 most highly
expressed GAS transcripts detected with both inoculat-
ing strains, an important finding given that Gls24 may be
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important for virulence in the murine invasive model of S.
pneumoniae infection.29 Other high-level GAS transcripts
detected in WT-infected tissues include the chromosomal
spd locus (ranked 14th) encoding a secreted DNase17;
sagA (ranked 28th) encoding a potent host cytolysin
called streptolysin S (SLS); dppA (ranked 47th) encoding
dipeptide binding protein; gap/plr (ranked 71st) and eno
(ranked 117th) encoding glycolytic enzymes glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) and -eno-
lase, respectively; scpA (ranked 84th) encoding C5a
peptidase; spyCEP (ranked 97th) encoding an IL-8-
cleaving surface proteinase30; lmb (ranked 192nd) en-
coding a laminin-binding surface adhesin,31 and spyA
(ranked 211th) encoding an ADP-ribosyl transferring exo-
toxin that disrupts host cell cytoskeletal structures.32 Sev-
eral GAS regulatory genes also had highly expressed
transcripts, including the repressor of class I heat shock
genes hrcA33 (ranked 15th), transcriptional regulator
RofA (ranked 30th) involved in modulating adhesin ex-
pression,8 ferric iron transport regulator PerR34 (ranked
130th), and the TCS designated Ihk/Irr (ranked 162nd/
288th), which is essential to GAS survival responses dur-
ing PMN interactions.35 Among the top 200 detected
GAS transcripts, 20 encode for products predicted (by
their amino acid sequences) as cell surface-associated
or secreted, whereas transcripts encoding experimen-
tally confirmed extracellular gene products such as SIC,
streptodornase (ranked 14th), Mn2-binding surface li-
poprotein designated MtsA (ranked 88th), and an immu-
nogenic secreted protein designated Isp2 (ranked 188th)
also were observed.
GAS Protective Response Augmented in the
Soft Tissue Environment
As described above, we detected elevated transcript
levels in WT-infected mouse tissues for genes involved in
oxidative stress protection and stress adaptation. These
transcripts also included genes encoding the reactive
oxygen-reducing enzymes superoxide dismutase SodA
(ranked 114th),36 peroxiredoxin reductase AhpC and
AhpF (ranked 115th and 147th),37 and NADH oxidase
NOX (ranked 129th),38 molecular scavengers such as the
antioxidant Dpr protein (ranked 76th),39 clpC (ranked
158th) encoding heat shock protease ClpC involved in
Figure 1. Histopathological assessment of GAS mouse skin infection. Photomicrographs of H&E-stained, formalin-fixed tissue biopsies taken from PBS-inoculated
(control) animals (top row), strain MGAS5005 (WT)-infected animals (middle row), and animals infected with covR mutant strain JRS950 (bottom row) at 2 days
after inoculation. Results are representative of tissues obtained from animals in each of the groups. Additional histopathology and gram stains of biopsies from
the same animals (D, G) are depicted in Figure 2, B and E and C and F, respectively. Original magnifications: 40 (A, D, G); 100 (B, E, H); 200 (C, F, I).
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tolerance to environmental stress,40 recA (ranked 169th)
encoding the RecA regulator of bacterial SOS responses,
and sortase SrtA (ranked 131st) involved in the matura-
tion of extracellular GAS proteins. Molecular chaperones
as well as DNA and protein repair functions (chaperone
proteases) also were elevated in soft tissues (Supple-
mentary Table 3, see http://ajp.amjpathol.org). Impor-
tantly, we also detected abundant transcripts encoding
products involved in GAS cell wall formation and modifi-
cation, including the murein transpeptidase-transglyco-
sylases PBP 1B and PBP 2A (ranked 29th and 149th,
respectively) and UDP-N-acetylmuramate-alanine ligase
(murC; ranked 151st) among others suggesting an im-
portant role in cell wall modifications or repair during
tissue infection.
Co-Expressed Transcripts
Numerous in vitro studies have demonstrated that emm,
sic, and mga are coregulated by the multigene transcrip-
tional activator called Mga. High correlation (r  0.9)
between co-expressed transcripts suggested that in ad-
dition to emm, sic, and mga, chromosomally adjacent
genes M5005_Spy1721-8 also are likely Mga regulon
members (Supplementary Table 4, see http://ajp.
amjpathol.org). These adjacent coding regions contain an
immunogenic secreted protein designated Isp; the Ihk/Irr
TCS; and members of an ATP-binding cassette transport
system of unknown function. High correlation (r  0.91)
between transcripts also was observed between eno,
encoding the surface-localized glycolytic enzyme -eno-
lase, and emm encoding the anti-phagocytic M1 protein
(data not shown). The latter represents an interesting and
new observation because these genes are distant on the
GAS chromosome, yet both encode proteins that interact
directly with host plasminogen.41
Analysis of Strain Effect in the Soft Tissue
Environment
GAS transcript correlations with transcription of covR/S
are shown in Supplementary Table 5 (see http://ajp.
amjpathol.org). In total, 76 GAS transcripts were differen-
tially expressed across WT versus covR mutant in the
lesions (Q  0.05; P  0.002; Figure 3; Supplementary
Table 3; Supplementary Figures 3 and 4, see http://
ajp.amjpathol.org). CovR acts as a transcriptional repres-
sor14,20,42–44, and therefore it was not unexpected that
the vast majority (n  50) of differentially expressed
transcripts were more abundant in tissues infected by the
covR strain as compared with the WT-type strain. Genes
or transcripts up-regulated as compared with WT condi-
tions (1.4-fold to 2.8  103-fold higher expression) en-
Figure 2. Gram stains of GAS during invasive soft tissue infection. Depicted are gram-stained skin tissue sections from mice infected with WT GAS strain
MGAS5005 (B, C) and covR mutant strain JRS950 (E, F). Also shown are the external pathologies for the same animals infected with WT (A) and covR mutant
(D). IHC analyses of biopsies from the same animals are depicted in Figure 5, B (WT) and D (Mutant), respectively. Original magnifications: 40 (B, E); 1000
(C, F).
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coded the secreted DNase streptodornase (spd); plas-
minogen activator streptokinase (ska); cysteine protease
(speB), and the entire streptolysin S (SLS) biosynthesis
locus (sagA-I). Up-regulated transcripts in the covR mu-
tant are generally associated with unknown functional
annotations (n  14), but only six were common with
up-regulated transcripts after ex vivo blood culture.20
However, carbohydrate metabolism (n  9); virulence
(n  8), and membrane transport (n  7) functions also
were statistically more significantly up-regulated than in
the WT. Noteworthy up-regulated transcripts include
genes coding for the 67-kd myosin-crossreactive
streptococcal antigen (M5005_Spy0385); hyaluronan
(capsule) synthesis enzyme HasA, and a cell wall-
modifying enzyme peptidoglycan amidohydrolase
(M5005_Spy0500). Conversely, one third of differen-
tially expressed transcripts (n  26) were significantly
less abundant in covR versus the WT-inoculated tis-
sues (1.5- to 12.6-fold reduced expression; Supple-
mentary Table 3, see http://ajp.amjpathol.org). To fur-
ther investigate transcriptome differences between WT
and covR-minus, we analyzed functional categories
that were overrepresented by gene-specific analysis
based on 10,000 permutations of array assignments, a
process previously described.26 Sixty-five GAS tran-
scripts achieved the minimum cutoff value (false dis-
covery rate 0.003). Numerous GAS transcripts en-
coding virulence-associated extracellular products
exhibited overexpression in covR-inoculated tissues
versus WT (Supplementary Figure 5; Supplementary
Table 6, see http://ajp.amjpathol.org), a finding seen
previously in in vitro experimental conditions.14,20 In
contrast, most transcripts involved in stress adaptation
were underexpressed in covR- versus WT-inoculated
tissues (Supplementary Figure 6; Supplementary Table
6, see http://ajp.amjpathol.org), suggesting that al-
though CovR acts primarily as a transcriptional repres-
sor for tissue damaging virulence factors, lack of this
repression may mean less stress adaptation is re-
quired within the localized environment. Virtually no
transcripts were detected for the activator of CovR
expression (designated RocA; Supplementary Table 3,
see http://ajp.amjpathol.org) suggesting that CovR is
modulated in vivo. Although we detected mid-range
levels of transcripts encoding CovR (ranked 269th) in
WT-infected tissues, CovR phosphorylation status de-
termines its DNA-binding (repressing) activity.45
Validation of Oligonucleotide-Array Gene
Expression (Transcript) Results
To validate the microarray data, we performed quantita-
tive reverse transcription RT-PCR (TaqMan) assays with
eight selected GAS transcripts (Figure 4). The transcript
detection rank orders were nearly identical with only
dppA and speA reciprocated across the two methods (in
rank order of abundance: sic, emm, dppA, slo, sceD, sclA,
speA, cfa in microarray dataset (Figure 4A) versus emm,
sic, speA, slo, sceD, sclA, dppA, cfa by TaqMan analysis
(Figure 4B). TaqMan assays detected much higher levels
of speA transcripts encoding the pyrogenic toxin supe-
rantigen PTSAg SpeA2, possibly resulting from use of the
single endogenous transcript (proS) in TaqMan assays
as opposed to use of all transcripts for normalizing mi-
croarrays. Strong positive correlation (r  0.87) was ob-
served overall for expression measurements obtained by
the two methods, and for all transcripts, concordance
was observed between methods for the direction (in-
crease versus decrease) of expression differences
across inoculating GAS strains.
Immunohistochemical Analysis of Mouse Tissue
In situ IHC with specific antibodies directed against 16
GAS proteins was used to detect proteins made from
identified transcripts. Absence of specific staining in neg-
ative control tissues confirmed lack of antibody cross-
reactivity (Figure 5). Seven of the 16 GAS-specific anti-
bodies were reactive in situ with several GAS antigens
demonstrating high levels of immunoreactivity or abun-
dance (Figure 5; Supplementary Table 7, see http://
ajp.amjpathol.org). Our detection of immunoreactivity of
PrsA protein (M5005_SPy1133; ranked 121st transcript)
supports previous observations of in vivo expression of a
PrtM homolog involved in protease maturation,27 a signif-
icant note, given that PrtM-immunized mice are protected
against S. pneumoniae infection.46 Despite limited detec-
tion of malE RNA transcripts (M5005_Spy1058; ranked
561st); a surprisingly high degree of immunoreactivity
was observed for the solute-binding surface lipoprotein
Figure 3. Analysis of variance revealed a significant strain effect in the in
vivo microarray expression data. The depicted box plot shows the confi-
dence of calls for strain effect in Q values (P values adjusted for multiple
testing using false discovery rate) on the horizontal axis versus GAS func-
tional category. A vertical line delineates the statistical significance threshold
(Q  0.05) for differentially expressed GAS transcripts in WT versus covR
mutant strain. The 76 identified differential transcripts in the in vivo tran-
scriptome data are primarily associated with carbohydrate metabolism, mem-
brane transport, signal transduction, stress adaptation, unknown functions,
and virulence.
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MalE, known to be involved in maltodextrin/maltosaccha-
ride uptake (see below). Immunoreactivity also was noted
in the IHCs for the extracellular virulence-associated pro-
teins PTSAg SpeA2 (M5005_Spy0996) and SIC (Supple-
mentary Table 7, see http://ajp.amjpathol.org), confirming
at the protein level the RNA expression of these two
important virulence genes.
Carbohydrate and Energy Metabolism
Contiguous coding regions (M5005_spy1062-7) involved
in the transport and catabolism of complex carbohy-
drates known as maltodextrins were among the highest-
expressed GAS transcripts detected in our in vivo data
(Supplementary Table 3, see http://ajp.amjpathol.org).
The corresponding genes encode a maltose/maltodextrin
utilization protein (MalA); a maltodextrin ATP-binding
cassette transport system (MalC and MalD); two en-
zymes involved in maltodextrin rearrangement (cycloma-
ltodextrin glucanotransferase AmyA and cyclomaltodex-
trinase AmyB), and a maltose/maltodextrin solute-binding
protein (MalX), respectively. Synchronous with these re-
sults, low transcript levels were detected for two nearby
genes encoding putative transcriptional repressors, the
maltose operon regulator MalR (M5005_spy1057) and an
inferred LacI-family regulator (designated herein as MalT;
M5005_spy1061), suggesting a cause and effect relation-
ship. Functionally related transcripts (M5005_spy1055-60)
also were detected adjacent to chromosome region
(M5005_spy1062-7), including genes encoding enzymes
maltodextrin phosphorylase (MalP/GlgP) and amylomaltase
(MalQ/MalM), and a maltose/maltosaccharide/maltodextrin-
binding ATP-binding cassette transport system (MalEFG).
Our analysis of coordinated expression of transcripts dis-
covered another functionally related locus nearby
(M5005_spy1680-2), that encoded the Mga-activated po-
lysaccharidase designated pullulanase47; a dextran gluco-
sidase, and a maltose/maltodextrin solute-binding protein
Figure 4. Verification of representative oligonucleotide microarray transcrip-
tome data. Depicted are GAS expression estimates for eight selected GAS
transcripts, as obtained by RMLChip microarray experiments (A) and real-
time RT-PCR (TaqMan) assays (B). Results depicted summarize the analysis
of 49 mice infected with either WT strain MGAS5005 (n  23; closed
symbols) or the isogenic covR mutant (n  26; open symbols) and are
expressed as median expression relative to the reference transcript proS
(M5005_spy1673). Asterisks depict transcripts detected as differentially
expressed at Q  0.001 in arrays (A) and in TaqMan assays at P  0.001
according to the Mann-Whitney rank sum test (B).
Figure 5. Immunohistochemical confirmation of GAS protein expression
during soft tissue infection. Representative IHC results for tissue obtained
from mice infected with GAS WT MGAS5005 (left) and covR mutant strain
JRS950 (right) analyzed with anti-M3.1/1-24 antibodies (negative control) (A);
anti-SPE A2; M5005_spy0996 (B); anti-MalE; M5005_spy 1058 (C); anti-Obp;
M5005_spy1308 (D); and anti-SIC; M5005_spy1718 rabbit polyclonal antisera
(E) at 2 days after inoculation.
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MsmK, suggesting that maltodextrin-related transcript co-
expression is likely important in GAS soft tissue infection.
Recent published findings suggested that transcripts
involved in maltodextrin metabolism (M5005_spy1061-7)
may be positively regulated by the TCS designated
SptR/S loci (M5005_Spy0680/1).48 However, we found no
correlation of malT-malX expression with either sptR or
sptS transcripts (r  0.5), whereas positive correlations
were revealed with transcripts encoding the TCS desig-
nated LytR/S, whose homologs affect cell wall metabo-
lism in Staphylococcus aureus49 (r  0.7; Supplementary
Table 4, see http://ajp.amjpathol.org). Strong correlation
with lytRS (r  0.85) was similarly observed for the chro-
mosomal region flanking lytRS (M5005_Spy1303-10),
which coincidentally encodes yet another putative com-
plex sugar transport system. Together, these findings
provide supporting evidence for involvement of the
CovR-regulated LytR/S TCS in mediating GAS complex
carbohydrate metabolism during soft tissue infection.
GAS ferments carbohydrates via the Embden-Meyer-
hof-Parnas (EMP) pathway to form pyruvate for energy
metabolism. As with many bacteria, glucose is the pre-
ferred catabolic substrate and high glucose concentra-
tions repress expression of alternative catabolic path-
ways via the catabolite repressor CcpA.50 We discovered
that ccpA was expressed at low range (ranked 342nd) in
the mouse tissues suggesting that glucose supplies were
limiting at that time. In agreement with this finding, high
levels of lactate oxidase (lctO; ranked 63rd) transcripts,
of which the protein product is known to convert lactate to
acetate thereby generating ATP via acetyl phosphate,51
were detected simultaneously (Supplementary Table 3,
see http://ajp.amjpathol.org). Together, these results sug-
gest a glucose-poor environment with adaptation by GAS
for using lactate as a carbon energy source during soft
tissue infection. Elevated transcripts also were detected
for pfl and pta encoding pyruvate formate-lyase and
phosphotransacetylase (ranked 81st and 102nd, respec-
tively), which are involved in pyruvate oxidation to coen-
zyme A and formate51 suggesting that metabolic path-
ways downstream of pyruvate were activated. However,
GAS also is capable of fermenting nitrogen-containing
compounds for energy metabolism generating 1 mol of
ATP per mol of arginine or histidine metabolized and high
levels of transcripts were detected for the histidine cata-
bolic pathway and histidine deaminase (hutH; ranked
90th), which generates urocanate and ammonia. Coordi-
nate with histidine catabolic pathway expression, a poly-
cistronic transcript (M5005_Spy1270-5) encoding argi-
nine deiminase (ADI; ranked 177th) along with transcripts
encoding other related functions within the arginine cat-
abolic pathway (Supplementary Table 3, see http://
ajp.amjpathol.org) were detected.
GAS Transcripts Correlated with Gross
Cutaneous Injury
Analysis of WT-inoculated tissue array data revealed 18
GAS transcripts whose expression correlated directly
with lesion volume (Q  0.05; Supplementary Table 8,
see http://ajp.amjpathol.org). Of these, six encode genes
of unknown function, whereas seven are localized in the
bacterial cytoplasm and involved in information process-
ing, including transcriptional repressor ArgR1 (M5005_
Spy1229; ranked 313th), the multigene transcriptional
activator Mga (ranked 418th), and the DNA mismatch
repair protein MutL (ranked 592nd). No GAS transcripts
exhibited significant correlation with erythema volume
(Q  0.05; data not shown).
Discussion
Bacterial pathogens use coordinated gene expression to
respond to environmental change and to elude host de-
fenses, thereby facilitating persistence, proliferation, in-
vasion, and dissemination. As GAS infects humans using
a variety of different routes (skin, mucosal surfaces, and
blood), it likely expresses distinct sets of genes that
enable it to adapt to each diverse and changing host
microenvironment.11 Current understanding of bacterial
gene regulation is based primarily on studies conducted
under controlled laboratory conditions, in which typically
only one variable is altered at a time. Although this ap-
proach is powerful in pathogenesis studies, it does not
adequately mimic the extensive variety of signals expe-
rienced simultaneously when bacteria are growing in the
host.12 Global expression microarray (transcriptome)
analysis of bacteria grown in vivo provides a unique op-
portunity to identify how pathogens adjust gene expression
genome-wide in response to complex host environments.10
Abundant GAS Transcripts in Soft Tissue
Infection
WT GAS is a superbly adapted pathogen, able to protect
itself against damaging host effectors during murine soft
tissue infection by expressing numerous anti-oxidant,
molecular chaperone, cytotoxin, and cell wall/lipoteichoic
acid modifying proteins. For example, we observed emm
transcript-encoding M protein, the hypervariable major
surface antigen used for serological typing of GAS
strains, predominate in lesions. This well-studied bacte-
rial virulence determinant acts as an adhesin; promotes
inflammation; impedes phagocytosis by binding comple-
ment control factors, fibrinogen, kininogen, and also plas-
minogen;3,4 and is abundantly transcribed during GAS
culture ex vivo in blood.20 Host fibrinogen levels rise
sharply during tissue inflammation and injury, and M
protein/fibrinogen complexes activate PMNs through 2-
crosslinking triggering release of heparin-binding protein
(HBP), a proinflammatory mediator which in turn pro-
motes excessive vascular leakage.52 Another important
molecule whose RNA was present in high amounts in our
tissue model was GAS cysteine protease SpeB, which
has been shown to cleave many host proteins including
cytokine precursors, cell receptors, fibrin, vitronectin,
matrix proteoglycans, cationic antimicrobial peptides,
and immunoglobulins, thereby contributing to endothelial
and epidermal damage, tissue destruction, and bacterial
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dissemination.53–55 SpeB enzymatic activity also re-
leases fragments of fibrinogen-complexed M1 protein
[fibrinogen-M1], thereby contributing to vascular leakage
and host tissue damage.52 However, at the same time,
we detected virtually no grab transcripts, which encode a
host protease inhibitor 2-macroglobulin-binding bacte-
rial surface protein designated GRAB. 2-Macroglobulin-
GRAB complexes concentrate SpeB activity at the bac-
terial surface and against smaller substrates, thereby
protecting GAS against killing by the antibacterial pep-
tide LL-37.56 Because SpeB also degrades many GAS
extracellular proteins in the absence of GRAB, not sur-
prisingly we detected modulated, mid-ranging speB tran-
scripts (ranked 304th in WT) at 7- to 25-fold lower levels
than the most abundantly detected GAS transcripts in
tissues. Therefore, in the soft tissue model we propose
that low levels of grab, moderate levels of speB, and high
emm1.0 transcript production occurs, providing sufficient
SpeB proteolytic activity and hence M1-fibrinogen com-
plex formation all of which leads to substantial tissue
damage. Increasing transcription of speB throughout
time during soft tissue infection has recently been de-
scribed.11 These observations, coupled with postinfec-
tious induction of tissue edema, which leads to depletion
of vascular volume, may account for the rapid onset of
life-threatening hypotension and shock in severe GAS
infections.7 Interruption of this pathophysiological path-
way could be critical for therapeutic intervention of ag-
gressive, invasive GAS infections.
During soft tissue infection, WT GAS expresses high
levels of transcripts for products that inhibit host innate
defenses and protect GAS against neutrophil-derived re-
active oxygen species and antimicrobial peptides. For
example, sic (ranked first) and spd (ranked 14th) were
among the most abundantly expressed GAS transcripts
measured. We confirmed the high expression levels of
SIC by IHC analysis of infected tissues (Figure 4). SIC is
known to inhibit complement-mediated bacterial lysis via
C5b67 binding, innate defenses such as lysozyme and
PMNs, and can eliminate chemotactic recruitment of leu-
kocytes, T cells, and mast cells by inactivating antimicro-
bial peptides such as LL-37 and -defensins.57,58 Similar
findings were observed in vivo in nonhuman primates and
after GAS culture ex vivo in whole blood where Mga
regulon transcripts were the highest expressed of all
detected regulons.10,20 On the other hand, streptodor-
nase (spd) is a secreted DNase that may interfere with
PMN function, by degradation of innate immune struc-
tures known as neutrophil extracellular traps.17,59 In ad-
dition, high levels of expression of sagA (ranked 28th),
which encodes the potent cytolysin SLS, was notable
because SLS is thought to accelerate necrotic fascial
injury through cytotoxic or apoptotic effects on many cell
types including, but not limited to, neutrophils.60 The
untranslated mRNA of the pleiotropic effect locus (pel),
which incidentally contains sagA, also acts as an anti-
sense RNA transcriptional regulator, augmenting GAS
virulence factor expression [SIC, M-protein, extracellular
NAD-glycohydrolase (NADase encoded by nga/spn),
plasminogen activator streptokinase encoded by ska,
and SpeB] when pel RNA expression is induced.61,62 We
detected abundant sagA transcripts; thus pel-induced
virulence gene expression may be predicted, as was
observed in this study for all but nga (ranked 780th in WT
extracts). Therefore, these results, when coupled with the
elevated expression of the neutrophil chemoattractant
(interleukin-8)-cleaving SpyCEP protease (ranked
97th),30 support the idea that coordinated, increased
expression of sic, spd, sagA, speB, and spyCEP likely
accounts for lack of inflammatory cells present at GAS
sites in deep tissues.63 Expression of the aforementioned
GAS products, along with M1 protein, streptokinase, and
the host cytolysins streptolysin O (SLO; ranked 268th)
and NADase likely contributes to much of the cu-
taneous and subcutaneous pathologies observed in
our animal model tissue infections (Supplementary Table
3; reviewed in Supplementary Table 9,64–84 see
http://ajp.amjpathol.org).
Serotype M1 strains are often associated with postin-
fectious sequelae, possibly resulting from immunological
cross-reactivity of GAS antigens with host tissues.3,4 Vir-
taneva and colleagues,10 observed during nonhuman
primate experimental pharyngitis, high in vivo levels of
GAS transcripts, such as emm, cardiolipin synthetase,
and myosin-cross reactive streptococcal antigen, results
we have now confirmed in our in vivo study; M protein
(emm, ranked seventh), hydroxylated phospholipid car-
diolipin synthetase (CL synthase, M5005_Spy0926;
ranked 111th), and 67-kd myosin-crossreactive strepto-
coccal antigen85 (M5005_Spy0385, ranked 125th). In-
creased production of these transcripts in both the oro-
pharynx model and now the soft-tissue model suggests
an increased risk of nonsuppurative sequelae, a pros-
pect that warrants further study.
Three proteins encoded by up-regulated WT tran-
scripts; gap/plr, eno, and ska, ranked 71st, 117th, and
453rd, respectively, are known to interact or bind with
host plasminogen.3 Fibrinogen binding to M-protein
(emm) leads to host plasminogen binding. Bound plas-
minogen interacts with GAS streptokinase to generate a
bacterial-bound, serine protease-designated plasmin.86
GAS surface-localized plasmin has been implicated in
GAS dissemination.3,41,74–86 Statistically higher expres-
sion of ska transcripts in the covR mutant likely contrib-
uted to lesion size differences between mutant and WT.
Our observation of abundant plr transcripts is also note-
worthy given that the encoded protein also has been
identified as an acute poststreptococcal glomerulone-
phritis-associated antigen (designated NAPlr).87,88
GAS is sensitive to penicillin in vitro, yet high-dose
penicillin demonstrates reduced bactericidal activity in
vivo, attributable in part to inadequate drug perfusion in
poorly vascularized or necrotic fascia.89 In addition, large
GAS inocula refractory to penicillin have been suggested
as metabolically inactive or demonstrating decreased
presence of penicillin-binding proteins (PBPs).7,90,91 At
the time point of our collected tissue samples, we de-
tected abundant levels of PBP1A- and PBP2A-encoding
transcripts and found no evidence suggesting inactive or
reduced metabolic activity in vivo. Previously published
studies have demonstrated that our custom high-density
array approach is capable of sensitive detection of low
936 Graham et al
AJP September 2006, Vol. 169, No. 3
copy transcripts.10 Therefore, the mechanisms responsi-
ble for reduced efficacy of penicillin treatment in vivo may
be more complex than previously thought, perhaps war-
ranting focused study. Although we observed abundant
GAS transcripts encoding proinflammatory M protein,
SLS cytotoxin, and plasmin receptor Plr (ranked seventh,
28th, and 71st, respectively), decreased protein expres-
sion encoded by these genes may explain why co-ad-
ministration of clindamycin (a protein synthesis inhibitor)
seems to enhance bacterial clearance in progressive
cases, relative to penicillin treatment alone.4,89 Future
investigations are warranted to elucidate this clindamycin
phenomenon.
Transcripts encoding GAS PTSAg exotoxins were vir-
tually undetectable at the time of our tissue sampling.
PTSAgs are potent T-cell mitogens that stimulate a mas-
sive release of inflammatory cytokines and that correlate
with severity of systemic clinical manifestations in GAS
infections.92 However, data observed in nonhuman pri-
mates suggest that PTSAgs SpeA2, SpeJ, and SmeZ
demonstrate differential expression before, during, and
after pharyngeal colonization.10 Our findings therefore
support clinical and experimental data revealing recipro-
cal, or temporal expression of SpeA and SpeB in vivo.93
Recent observations suggest that direct contact with hu-
man PBMCs, which occurs early in infection, induces
SpeA expression94 whereas cysteine protease SpeB ex-
pression increases temporally during later stages of soft
tissue infections.11 Our in situ immunohistochemical data
showed immunoreactivity for SpeA at 48 hours after in-
oculation. Numerous GAS proteins are known to contrib-
ute to the induction of neutrophil apoptosis,69 leading to
an absence of proinflammatory cells at GAS sites in deep
tissues.63 Together, these findings do not preclude the
expression of PTSAg exotoxins at early stages of soft
tissue infection, but rather suggest that the time we har-
vested the tissue (2.5 days after infection) was more likely
a mid point during the GAS soft tissue infection time
course.
Adaptive Metabolism
Central and adaptive metabolism profoundly affects
pathogen persistence in vivo and likely accounts for why
GAS regulatory- and metabolism-associated transcripts
(primarily cytoplasmic) predominate in soft tissues. We
found that in vivo GAS abundantly transcribes genes in
two chromosomal regions (M5005_spy1062-7 and 1680-
2), which are involved in metabolizing complex carbohy-
drates such as maltodextrins, which may include but not
be limited to glycogen, maltotetraose, maltotriose, and
maltose. These expression results are consistent with a
report in which 81% of convalescent-phase sera from
patients with invasive GAS infections had antibodies re-
active with M5005_SPy1680, also known as pullulanase
(PulA).95 PulA is a polysaccharidase that is positively
regulated by the multigene transcriptional activator
called Mga and which uses host glycoproteins as its
enzymatic substrate.47 GAS metabolism of complex host-
derived carbohydrates may be particularly important dur-
ing soft tissue infections because of abundant host gly-
coproteins and host cell contents released during cell
lysis. Degradation of host proteins in necrotic fascia may
contribute to fermentation of arginine and histidine during
soft tissue infection. In turn, fermentation of amino acids
produces ammonia, which could beneficially neutralize
surrounding pH thereby protecting GAS from acid-in-
duced damage.96 GAS arginine deaminase activity has
been linked to inhibition of human peripheral blood
mononuclear cell proliferation.97 The arginine deiminase
system of Streptococcus suis is induced by arginine, el-
evated temperature, and reduced oxygen tension, and is
subject to carbon catabolite repression.98 Therefore, low
glucose and hypoxic microenvironments, after vascular
injury, may serve as signals that trigger the GAS adaptive
response, which in turn enables bacterial persistence
and proliferation in soft tissues.
GAS Transcript Expression Is Not Correlated
with Cutaneous Injury
Correlation analysis of GAS transcripts with cutaneous
lesion volume produced only a few candidates (n 
18), most of which appear to encode proteins pre-
dicted to be cytoplasmic or membrane-bound in func-
tion. Although these discoveries are attractive, lack of
biochemical functional annotation for these genes lim-
its our ability to hypothesize their role in lesion devel-
opment. These findings are consistent with the clinical
observation that substantial necrosis occurs subcuta-
neously in some human infections without overt injury
of the overlying skin.13 Further studies are needed to
identify bacterial genes associated with soft tissue dis-
ease severity and the functions they may impart in this
important aspect of disease.
GAS Strain Comparison in Vivo
The CovR response regulator has been shown to play
a central role in GAS regulatory networks by directly or
indirectly influencing expression of 15% of all GAS
chromosomal genes during in vitro growth.14 CovR
negatively regulates biosynthesis of the anti-phago-
cytic hyaluronic acid capsule42 and the expression of
numerous cell-surface-associated and secreted pro-
teins known to promote survival or impart virulence in
humans.14,42– 44 Hyperencapsulated GAS variants with
spontaneous covR/S mutations have been isolated af-
ter WT bacterial passage in human blood, passage in
mice, or after natural-acquired human infections.99 –101
Importantly, high GAS bacterial colony-forming unit
numbers has been found to negatively correlate with
covR expression in vivo during acute phase GAS phar-
yngitis in primates.10 Despite absence of CovR func-
tion in the mutant strain, we found fewer differentially
expressed transcripts (n  76) between mutant and
WT during soft tissue infection than we had extrapo-
lated from our previous in vitro studies.14,20 This led us
to hypothesize that transcription of covR in WT GAS
occurs at lower levels in vivo during soft tissue infection
GAS Transcriptome in Soft Tissue Infection 937
AJP September 2006, Vol. 169, No. 3
at the time point studied than under in vitro growth
conditions. Indeed, covR and covS transcripts ranked
269th and 755th, respectively, in GAS-infected lesion
extracts, whereas covR/covS transcripts were more
abundant (transcripts ranked 30th to 280th) during a
90-minute time course of culturing in human blood ex
vivo.20 This finding supports in vivo down-regulation of
covR expression,10,99 –101 leading to increased viru-
lence factor production14 and resultant tissue pathol-
ogy and suggests that soft tissue effectors not present
in whole blood are likely responsible for this down-
regulation. Based on in vitro studies, high [Mg2] con-
centration has been proposed as an environmental
stimulus responsible for up-regulation of CovR/S ex-
pression and therefore repression of the expression of
CovR-regulated genes.102 In vivo microenvironment
analysis of magnesium concentrations throughout
time, during the course of soft tissue infections may
provide insight into the effectors regulating CovR/S
expression.
In contrast to in vitro findings,14,20 more than half of the
total number of transcripts functionally related to stress
adaptation were transcribed at lower levels in vivo in the
covR mutant as compared with the WT. Given that we
detected more transcripts encoding the transcriptional
repressor of class I stress genes (designated HrcA)33 in
WT (ranked 15th) than in mutant (ranked 42nd), we would
predict the converse; that transcript levels encoding the
negatively regulated class I molecular chaperones
(DnaJ, DnaK, and GroES) and chaperone proteases
(GroEL, ClpP, and ClpL) would be higher in covR-in-
fected tissues as compared with WT extracts. These
results imply other peripheral regulatory mechanisms
may be in place, and suggest that less stress adaptation
may be required in the localized environment when host
cell damaging virulence factors are derepressed. This
finding serves to highlight the importance of conducting
in vivo analyses to improve understanding of pathogen-
host interactions.12
Emerging Model of GAS Gene Regulation in
Vivo
Our study has provided the first in vivo analysis of GAS
gene expression during soft tissue infection. By differen-
tial gene expression, GAS successfully transitions
through three stages of host infection: namely, 1) estab-
lishment of infection, 2) adaptation, and 3) dissemination
(Figure 6). Information about stage 1 is based on an
expanding body of work,8,10,11,34,103 and our results sup-
port this information by combined early expression of
Mga, Ihk/Irr, and FasBCA/X regulatory systems that pro-
mote evasion of immune and innate host defenses and
enhance host cell contact through surface adhesin pro-
duction. Down-regulation of the negative regulatory sys-
tems of PerR, CovR/S, and CrgR promote production of
reactive oxygen species detoxifying enzymes, hyaluronic
acid capsule, and antimicrobial peptide resistance
mechanisms, respectively,8,35,103–107 and our soft tissue
model demonstrates similar results. Interestingly, we
have discovered that transcription of transport and cen-
tral metabolism genes appears tailored to unique GAS
environments where host glycopeptides and complex
carbohydrates are available, including maltodextrins, but
which must be used under acidic and hypoxic condi-
tions. Alteration of these conditions ultimately enables
GAS to persist and proliferate. GAS cell wall modifica-
tions can reduce cell permeability and thereby increases
antimicrobial peptide resistance.108 The reduced effi-
cacy of penicillin-based antibiotics in treating circulation-
poor deep-seated GAS infections also may be related to
this GAS adaptation. Throughout time, production and
accumulation of the SLS cytolysin, SpeB cysteine pro-
tease, proinflammatory PTSAgs, and fibrinogen-M1 pro-
tein complexes have the ability to cause cumulative dam-
age to host cells, resulting in disruption of host barriers
leading to bacterial dissemination. Evidence suggests
that dissemination of GAS from localized tissues, occurs
as GAS undergoes additional remodeling, which can
include late-stage cysteine protease expression,11 (Fig-
ure 6). A carbon catabolite response element (cre) oper-
ator site precedes the Mga promoter, and thus expres-
sion of Mga (and virulence factors it transcriptionally
activates) may be subject to carbon catabolite control.109
Linkage of the Mga regulon to GAS nutritional require-
ments may help explain why in our study we observed
correlated expression between eno encoding glycolytic
and surface -enolase and emm encoding M1 protein.
The linkage of GAS metabolism regulation and virulence
factor expression to nutritional signals provides an intui-
tive model that helps explain GAS movement from
chronic or acute sites to naı̈ve sites.
Few studies to date have succeeded in measuring global
transcription in the in vivo host environment.10,110–113 This
study has overcome difficult technical hurdles to provide a
unique dataset on the GAS transcriptome during soft tissue
infection. Twenty to thirty percent of many pathogen ge-
nome ORFs lack biochemical functional annotation. Our
transcriptome data suggest that many of these hypothetical
ORFs of unknown function are expressed in the soft tissue
model, often with good correlation to other virulence factors
and pathology. Our data provides new avenues of study for
determining the role of these hypotheticals and whether
diagnostic or vaccine candidates exist within this group of
genes. Owing to the fact that bacterial sampling required
animal sacrifice, our end-point study probed mid and late
stages of infection (stages 2 and 3, Figure 6). The propor-
tion of adapting versus disseminating bacteria in the tissue
extracts cannot be known and thus, the transcriptomes
obtained represent averages for the bacterial population.
Future studies will involve optimization and protocol devel-
opment for sensitive array analysis of microscopic tissue
biopsies collected throughout time after low-dose intrader-
mal inoculation. These experiments will provide a GAS tran-
scriptome profile of the temporal natural history of soft tissue
infection. In addition, we anticipate future tissue model stud-
ies will also focus on the comparison of in vivo GAS tran-
scriptomes of epidemiologically distinct strains. Last, al-
though our infection model mimics conditions present in
infected humans, we acknowledge that mice cannot ade-
quately replicate either the highly complex environment that
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GAS encounters in the infected human host or the human
host response. Future bacterial expression studies should
also be performed during natural human infections, pro-
vided appropriate precautions are taken to minimize tech-
nical variation and to adequately account for patient-to-
patient variability associated with the nature and logistics of
clinical specimen sampling, which often occurs under life-
saving and time-constrained circumstances involving pa-
tients recently treated with antimicrobial agents. Correlation
analysis will help pinpoint those GAS genes or ORFs ex-
pressed in common during different stages of disease,
which may lead to novel, broad-spectrum therapeutic, vac-
cine, or diagnostic candidates against this important human
pathogen.
Concluding Statement
A full understanding of host/pathogen interactions re-
quires knowledge of gene expression in vivo.10,12,114–116
Our data provide new information about GAS gene ex-
pression during soft tissue infection, and highlight the
benefit of using sensitive high-density microarray analy-
sis. The in vivo, soft tissue GAS transcriptome differs
significantly from that obtained in blood ex vivo,20 in iso-
lated cell populations,35 and during colonization and
acute pharyngitis,10 stressing the ability of GAS to alter its
transcriptome to permit growth in the different host envi-
ronments. Our results unambiguously demonstrate that
many proven and putative GAS virulence factors are
transcribed in vivo and contribute to extensive cellular
pathology observed in GAS soft tissue infections. Our
study provides the first genome-wide view of the GAS
transcriptome, in vivo, during skin infection and suggests
numerous avenues for investigation into targeted thera-
peutics against this important human pathogen. This
analysis framework is cross-applicable for examining
other pathogens causing invasive infections.
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